Med BioGene Inc. (MBI) is a Canada-based life science company. The Company is focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The Company is also focused on managing the license and rights to GeneFx Lung, a prognostic genomic-based test for non-small-cell lung cancer (NSCLC). The Company markets various tests through its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, including ChemoFx, BioSpeciFx, iRview mets2 and GeneFx Colon. Both GeneFx Colon and GeneFx Lung are gene expression-based tests and, accordingly, share the brand name GeneFx. Early-stage NSCLC patients are treated primarily by surgical removal of their tumors. Recent clinical trials have shown that adjuvant chemotherapy, administered after tumor removal improves the survival of stage II patient.